Third Pole Therapeutics Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
2ndary - Private
- Investors
-
4
Third Pole Therapeutics General Information
Description
Developer of tankless inhaled nitric oxide delivery systems designed for cardiopulmonary therapy. The company offers scalable technology that generates nitric oxide for inhalation instantly from electricity and ambient air, enabling medical practitioners to provide heart and lung-failure patients with life-sustaining nitric oxide therapy at home or while traveling without heavy gas tanks.
Contact Information
Website
www.pole3.comCorporate Office
- 309 Waverly Oaks Road
- Suite 404
- Waltham, MA 02452
- United States
Corporate Office
- 309 Waverly Oaks Road
- Suite 404
- Waltham, MA 02452
- United States
Third Pole Therapeutics Timeline
Third Pole Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Secondary Transaction - Private | 01-Nov-2025 | Completed | Pre-Clinical Trials | |||
| 12. Later Stage VC (Series B) | 13-Mar-2025 | Completed | Pre-Clinical Trials | |||
| 11. Later Stage VC (Series B) | 06-Feb-2024 | Completed | Pre-Clinical Trials | |||
| 10. Later Stage VC (Series B) | 03-Feb-2022 | Completed | Pre-Clinical Trials | |||
| 9. Debt - General | 15-Apr-2021 | Completed | Product Development | |||
| 8. Grant | 01-Jan-2021 | Completed | Product Development | |||
| 7. Debt - PPP | 14-Apr-2020 | Completed | Product Development | |||
| 6. Grant | 01-Sep-2019 | Completed | Product Development | |||
| 5. Early Stage VC (Series A) | 16-Jan-2018 | $13.8M | $13.8M | Completed | Product Development | |
| 4. Accelerator/Incubator | 15-Sep-2017 | Completed | Startup |
Third Pole Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B4 | ||||||||
| Series B2 | ||||||||
| Series B3 | ||||||||
| Series B1 | 2,800,000 | $0.001000 | 6% | $32.89 | $32.89 | 1x | $32.89 | 42.59% |
| Series A | 875,000 | $0.001000 | 8% | $20 | $20 | 1x | $20 | 13.31% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Third Pole Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Third Pole Therapeutics Patents
Third Pole Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250281686-A1 | Delivery of medicinal gas in a liquid medium | Pending | 24-Oct-2023 | ||
| US-20250368510-A1 | Methods and systems for removing contaminants from gas | Pending | 14-Feb-2023 | ||
| WO-2024173606-A1 | Methods and systems for removing contaminants from gas | Inactive | 14-Feb-2023 | ||
| AU-2024214184-A1 | Systems and methods for nitric oxide delivery | Pending | 30-Jan-2023 | ||
| EP-4658615-A1 | Systems and methods for nitric oxide delivery | Pending | 30-Jan-2023 | C01B21/203 |
Third Pole Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Third Pole Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Acorn Campus Taiwan | Venture Capital | Minority | ||
| Unorthodox Ventures | Venture Capital | Minority | ||
| National Heart, Lung, and Blood Institute | Government | |||
| National Institutes of Health | Government |
Third Pole Therapeutics FAQs
-
When was Third Pole Therapeutics founded?
Third Pole Therapeutics was founded in 2014.
-
Where is Third Pole Therapeutics headquartered?
Third Pole Therapeutics is headquartered in Waltham, MA.
-
What is the size of Third Pole Therapeutics?
Third Pole Therapeutics has 31 total employees.
-
What industry is Third Pole Therapeutics in?
Third Pole Therapeutics’s primary industry is Therapeutic Devices.
-
Is Third Pole Therapeutics a private or public company?
Third Pole Therapeutics is a Private company.
-
What is Third Pole Therapeutics’s current revenue?
The current revenue for Third Pole Therapeutics is .
-
How much funding has Third Pole Therapeutics raised over time?
Third Pole Therapeutics has raised $126M.
-
Who are Third Pole Therapeutics’s investors?
Acorn Campus Taiwan, Unorthodox Ventures, National Heart, Lung, and Blood Institute, and National Institutes of Health have invested in Third Pole Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
